• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alpha Cognition Inc (OP: ACOGF )

    0.4750 +0.0250 (+5.56%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 110,176
    Open 0.5200
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.4500
    Today's Range 0.4402 - 0.5200
    52wk Range 0.2288 - 0.7398
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
    From Alpha Cognition Inc.
    Via Business Wire

    Performance

    YTD
    -5.00%
    -5.00%
    1 Month
    -4.45%
    -4.45%
    3 Month
    -13.64%
    -13.64%
    6 Month
    -16.89%
    -16.89%
    1 Year
    +85.91%
    +85.91%

    More News

    Read More
    Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
    From Virtual Investor Conferences
    Via GlobeNewswire
    Alpha Cognition to Present at the Life Science Investor Forum March 7th
    From Virtual Investor Conferences
    Via GlobeNewswire
    Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Provides Business Update
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
    From Alpha Cognition Inc.
    Via Business Wire
    Life Science Investor Forum: Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    Life Science Investor Forum Agenda Announced for June 22nd
    From Virtual Investor Conferences
    Via GlobeNewswire
    Alpha Cognition Launches $6.5 Million Private Placement
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Provides Private Placement Update
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602
    From Alpha Cognition Inc.
    Via Business Wire
    Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment
    From Alpha Cognition Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.